Aurobindo Pharma

Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2025 ,inter alia, to consider and...

24 Oct, 2025 | 04:05pm • Source: BSE

Aurobindo Pharma Limited has informed the Exchange about Incorporation of a step down subsidiary in Chile viz Eugia Pharma Chile SpA

23 Oct, 2025 | 10:31am • Source: NSE

Aurobindo Pharma Limited has informed the Exchange about Incorporation of a step down subsidiary viz Aurobindo Pharma Chile SpA

23 Oct, 2025 | 10:29am • Source: NSE

Submission of notice published in newspapers regarding relodgement of transfer requests of physical shares.

16 Oct, 2025 | 12:51pm • Source: BSE

Submission of certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018

07 Oct, 2025 | 06:20pm • Source: BSE

Intimation of resignation of Mr. S. Venkatesh Kumar as Associate Vice President, Engineering Purchases.

01 Oct, 2025 | 12:19pm • Source: BSE

Intimation of completion of transfer of shares among subsidiary companies.

01 Oct, 2025 | 12:00pm • Source: BSE

Intimation of incorporation of CuraTeQ Biologics (Malta) Limited, a new wholly owned stepdown subsidiary.

26 Sep, 2025 | 06:14pm • Source: BSE

Update on transfer of shares among subsidiary companies.

26 Sep, 2025 | 05:30pm • Source: BSE

Update on acquistion of 26% stake in Swarnaakshu Solar Power Private Limited.

26 Sep, 2025 | 03:54pm • Source: BSE

Intimation of closure of trading window.

24 Sep, 2025 | 12:32pm • Source: BSE

Aurobindo Pharma Limited has informed the Exchange about fire accident at Unit-IV of APL Healthcare Limited, a WOS of the Company

19 Sep, 2025 | 01:33pm • Source: NSE

Intimation of fire accident at Unit 4 of APL Healthcare Limited, a wholly owned subsidiary of the Company.

19 Sep, 2025 | 01:24pm • Source: BSE

Aurobindo Pharma Limited has informed the Exchange about completion Phase 3 Clinical Study for Denosumab Biosimilar vy CuaTeQ Biologics

19 Sep, 2025 | 10:24am • Source: NSE

Submission of disclosure of successful of phase 3 clinical study for Denosumab Biosimilar by CuraTeQ Biologics Private Limited, a wholly owned subsidiary of the Company.

19 Sep, 2025 | 10:19am • Source: BSE

Intimation of incorporation of a wholly owned step-down subsidiary in Malaysia.

17 Sep, 2025 | 05:24pm • Source: BSE

Submission of Clarification Letter on significant movement in Volume of shares

12 Sep, 2025 | 02:25pm • Source: BSE

The Exchange has sought clarification from Aurobindo Pharma Ltd on September 12, 2025, with reference to Movement in Volume. <BR><BR>The reply is awaited.

12 Sep, 2025 | 01:21pm • Source: BSE

Submission of Voting Results of 38th AGM along with Scrutinizer Report.

11 Sep, 2025 | 05:33pm • Source: BSE

Submission of Proceedings of 38th AGM of the Company held on September 10, 2025.

10 Sep, 2025 | 05:52pm • Source: BSE